Andrew J. Yee MD

Hematologic Oncology

Assistant Professor of Medicine, Harvard Medical School, Massachusetts General Hospital Cancer Center

55 Fruit StYawkey 9ABoston, MA 02114
Phone+1 617-724-4000

Dr. Yee is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Yee's full profile Already have an account?

Summary

Dr. Andrew J. Yee is an oncologist in Boston, MA and is affiliated with multiple hospitals in the area, including Massachusetts General Hospital and North Shore Medical Center. He is an Assistant Professor of Medicine at Harvard Medical School. He received his medical degree from Harvard Medical School and has been in practice 17 years. He specializes in hematologic oncology and is experienced in amyloidosis, hematologic oncology, myelodysplasia, myelofibrosis, and multiple myeloma.

Education & Training

Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2004 - 2007
Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 2000 - 2003
Harvard Medical SchoolClass of 2000

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

NH State Medical License 2009 - 2027
MA State Medical License 2002 - 2026
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification Longitudinal Medical Record, Partners Healthcare System, 2012, 2014, 2016-2017
CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014, 2016-2017
CMS Meaningful Use Stage 1 Certification Partners Longitudinal Medical Record, Partners Healthcare System, 2012, 2014, 2016-2017

Clinical Trials

Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
ACTIVE_NOT_RECRUITING
PHASE1
Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM)
COMPLETED
PHASE2

Publications & Presentations

PubMed

Unilateral Optic Disc Edema in the Setting of Contralateral Intravitreal Anti-VEGF Injections as the presenting finding in POEMS Syndrome.
Marisa Tieger, Mary C Boulanger, Andrew J Yee, Emily M Hartsough, Dean Cestari
Journal of Vitreoretinal Diseases. 2026-05-25
2 citations
Ruxolitinib for ciltacabtagene autoleucel-associated refractory diarrhea.
Viktoria Blumenberg, Filippo Birocchi, Angela Shih, Giulia Escobar, Adele Mucci
Blood. 2026-05-07
Immune effector cell-associated enterocolitis post-BCMA directed CAR T-cell therapy: insights from a multicenter case series.
Sandra Susanibar-Adaniya, Benjamin A Derman, Adam D Cohen, Dan T Vogl, Shambavi Richard
Blood Cancer Journal. 2026-04-28

Lectures

Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Analysis of Hospitalization and Readmissions after CAR T Cell Therapy
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RVD) Combination Therapy for Patients with Newly Diagnosed Mult...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Year in Review: Multiple MyelomaNovember 3rd, 2025
Multiple Myeloma: Novel Quad Regimen Eases ToxicitySeptember 24th, 2025
Upcoming Alliance Webinar Showcases Cutting-Edge Advances in Cancer TreatmentFebruary 27th, 2026